Life Science ABM: Why Most Programs Stall Before They Scale

Life science account based marketing is a targeting strategy where sales and marketing coordinate efforts around a defined set of high-value accounts, typically biopharma companies, medical device manufacturers, CROs, or health systems, rather than broadcasting to a broad market. Done well, it concentrates resources where commercial returns are highest and gives enterprise sales teams the air cover they need to open and progress complex deals.

The challenge is that most life science ABM programs look rigorous on paper and underperform in practice. The account list is too long, the content is too generic, and the sales team was never genuinely involved in building the strategy. This article is about why that happens and what a tighter program actually looks like.

Why Life Science Is a Structurally Good Fit for ABM

ABM as a methodology suits markets with a finite number of high-value accounts, long sales cycles, complex buying committees, and high deal values. Life science checks every one of those boxes.

The addressable universe for most life science vendors is not millions of companies. If you are selling clinical data management software, manufacturing execution systems for biologics, or regulatory consulting services, you are probably talking about a few thousand organisations globally, and a few hundred that are genuinely worth pursuing in any given year. That structural scarcity makes broad demand generation a poor fit and targeted account work a logical one.

The buying process reinforces this. A procurement decision at a mid-size biopharma company might involve a VP of Clinical Operations, a Chief Medical Officer, procurement, IT, legal, and a project manager who will actually run the implementation. These people have different priorities, different vocabularies, and different reasons to care about your solution. A single campaign cannot speak to all of them. A well-constructed ABM program can.

I have spent time working with clients across healthcare and life science, and one pattern shows up reliably: the vendors who win enterprise deals in this space are almost always better at multi-threading than their competitors. They are not necessarily running the slickest campaigns. They are the ones who have figured out how to be relevant to four or five people inside the same account at the same time. ABM, when it is built correctly, is the operational framework that makes that possible.

If you want to think about ABM in the context of broader sales and marketing alignment, the Sales Enablement and Alignment hub covers the structural issues that sit underneath most of these programs, including why marketing and sales so frequently pull in different directions even when they nominally agree on strategy.

What Makes Life Science ABM Different From Standard B2B ABM

The principles of ABM are consistent across industries. The execution in life science has specific constraints that most generic ABM frameworks do not account for.

The first is regulatory and compliance context. Life science companies operate under FDA, EMA, and equivalent regulatory frameworks depending on their geography and product category. Vendors selling into this space, particularly in areas like clinical technology, medical devices, or pharmaceutical manufacturing, often face their own compliance requirements around how they market and communicate. Claims need to be defensible. Content that would be standard in a SaaS context can create problems in a regulated environment. This is not a reason to avoid content-led ABM, but it changes the brief considerably.

The second is the pace of the buying cycle. Enterprise deals in biopharma can run 12 to 24 months from first engagement to contract. ABM programs designed around 90-day sprints will consistently misread their own performance. An account that looks dormant at month three might be in active internal evaluation. Patience is not a soft skill here, it is a measurement requirement.

The third is the nature of the buying committee itself. Forrester has written about the changing shape of B2B buying influence, and in life science this is particularly pronounced. Decisions are rarely made by one person. Scientific credibility matters. A Head of Regulatory Affairs will not be persuaded by the same content that resonates with a Chief Procurement Officer. And increasingly, external advisors, KOLs (key opinion leaders), and consultants play a role in shaping vendor selection before procurement is ever formally involved.

The fourth is data availability. Firmographic and technographic data for life science accounts is patchier than in technology markets. Intent data signals are less reliable. You often know less about what an account is actively researching than you would in a software or financial services context. This means ABM in life science relies more heavily on direct sales intelligence and less on third-party signal aggregation than the ABM software vendors would have you believe.

How to Build an Account List That Is Actually Usable

The most common ABM failure I see is not a content problem or a technology problem. It is an account selection problem. Teams build a list of 300 accounts, call it ABM, and then run the same campaign to all of them with minimal personalisation. That is not ABM. That is segmented demand generation with a different label.

A workable life science ABM account list starts with a conversation between marketing and sales about what an ideal account actually looks like. Not a theoretical ICP document produced by marketing and filed away, but a genuine working session where sales leaders name the accounts they would most want to be in front of and explain why. That conversation surfaces the commercial logic that should drive the list.

From there, the list needs to be tiered. Tier one accounts, typically 10 to 30 for most life science vendors, get fully personalised treatment: bespoke content, direct outreach sequencing, executive engagement programs, and regular account reviews. Tier two accounts, perhaps 50 to 100, get industry-personalised content and coordinated outreach. Tier three is closer to traditional demand generation with account-level tracking layered on top.

The discipline is in keeping tier one genuinely small. Every time I have seen a tier one list creep above 40 or 50 accounts, the personalisation degrades, the sales team loses confidence in the program, and the whole thing starts to look like a spreadsheet exercise rather than a commercial strategy.

Account selection criteria worth building into the model include: current revenue potential, strategic fit with your product roadmap, likelihood of competitive displacement, existing relationships within the account, and timing signals from the sales team. Combining these into a simple scoring framework keeps the list defensible and gives you a basis for reviewing it quarterly.

Content Strategy for a Regulated Buying Environment

Content in life science ABM has to do more work than in most B2B contexts because the buyer is typically more technically sophisticated, more risk-averse, and more sceptical of vendor claims. A white paper that would land well with a marketing director at a SaaS company will often fall flat with a VP of Clinical Operations who has seen 20 vendors make similar claims and watched half of them fail to deliver.

What works is specificity. Case studies from comparable therapeutic areas or development stages. Technical documentation that demonstrates depth, not just breadth. Regulatory insight that shows you understand the environment your buyer is operating in. Peer validation from KOLs or industry bodies that carry credibility with a scientific audience.

Early in my career, I learned a lesson about specificity that has stayed with me. I was working on a campaign for a client in a technical services category, and we had two versions of an email: one that was broadly positioned and one that referenced a specific challenge the target audience was known to be facing at that moment. The specific version outperformed the generic one by a margin that was not close. The principle holds in life science ABM. Generic content, however well produced, does not move sophisticated buyers.

The content architecture for tier one accounts should map to the buying committee, not just the primary contact. That means separate content tracks for scientific, operational, and commercial stakeholders. It means understanding what each persona needs to feel confident recommending your solution internally. And it means producing content that helps your champion make the case to people you may never speak to directly.

Regulatory constraints shape the content brief in practical ways. Claims need to be substantiated. Comparative statements need to be handled carefully. In some segments, particularly medical devices and diagnostics, there are specific rules around promotional content that need legal sign-off. Building a content review process into the ABM workflow is not optional. Building it in early, before content is written rather than after, saves significant time and frustration.

Channel Mix and Activation in Life Science ABM

Life science buyers are not hard to find online, but they are selective about what they engage with. LinkedIn remains the most reliable paid channel for reaching senior decision-makers in biopharma and medical devices. Account-matched audiences, job function targeting, and company list uploads give you reasonable precision at the account level. The cost-per-click is high, but the alternative is wasting budget on audiences that will never convert.

Email works when it is genuinely personalised and sent from a person rather than a platform. Sequences from the account executive, referencing specific account context, consistently outperform broadcast nurture programs in this segment. The volume is lower, the effort is higher, and the results are better. That trade-off is worth making for tier one accounts.

Industry events and conferences remain important in life science in a way that has not fully translated to other B2B sectors. BIO, JPMorgan Healthcare, DIA, RAPS, and dozens of smaller specialist conferences are genuine relationship-building environments. Integrating event activity into your ABM calendar, using pre-event outreach to secure meetings and post-event follow-up to advance conversations, turns a significant cost centre into a measurable pipeline activity.

Direct mail is underused in life science ABM and worth considering for tier one accounts. A well-produced physical piece sent to a named executive at a target account cuts through in a way that the fifteenth LinkedIn message does not. I have seen this work particularly well in combination with a digital touchpoint, where the physical piece creates awareness that makes the digital follow-up feel less cold.

What does not work well is programmatic display targeting at the account level. The intent signal quality for life science accounts is inconsistent, the brand safety environment on open exchanges is unreliable, and the engagement rates rarely justify the investment. If you are going to use programmatic, run it as a light-touch brand presence layer on top of your higher-quality channels, not as a primary activation.

Measurement That Reflects How Life Science Deals Actually Work

Measuring ABM in life science requires resisting the pull of metrics that feel familiar but do not fit the model. Lead volume is the wrong primary metric for a program built around a finite account list. Cost per lead is almost meaningless when you are running bespoke programs for 20 accounts. Click-through rates tell you something about content relevance but nothing about commercial progress.

The metrics that matter are account engagement depth (how many people within a target account have engaged with your content or sales team, and how recently), pipeline influence (which opportunities in your CRM have had meaningful ABM touchpoints, and how does their close rate compare to those that have not), and account progression (are target accounts moving through defined stages, from unaware to engaged to in-process, over time).

I spent a period of my career judging the Effie Awards, which are specifically focused on marketing effectiveness. One thing that experience reinforced is how rarely marketers connect their activity to a business outcome in a way that is both honest and specific. The entries that stood out were the ones that could draw a clear line from what they did to what changed commercially. ABM measurement should be held to the same standard. If you cannot explain how your program is influencing pipeline, it is worth asking whether you are running ABM or running a content program with account-level branding on it.

Reporting cadence matters too. Monthly reviews at the account level, with sales and marketing in the same room, are the mechanism that keeps the program honest. Without that cadence, account lists drift, content becomes generic, and the program slowly reverts to something that looks like demand generation.

Sales and Marketing Alignment as the Operational Foundation

Life science ABM does not work as a marketing-only program. It requires sales involvement at every stage: account selection, account intelligence gathering, content briefing, and outreach coordination. The marketing team provides reach, content, and coordination. The sales team provides account knowledge, relationship access, and commercial judgment. Neither can do the other’s job.

The practical challenge is that sales and marketing in life science companies often have structurally different incentives. Sales teams are measured on quarterly pipeline and closed revenue. Marketing teams are often measured on MQLs, website traffic, or campaign reach. These metrics point in different directions. A sales leader who is under pressure to close deals this quarter has limited patience for a marketing program that is designed to influence deals 18 months from now.

Resolving this requires shared metrics and shared accountability, which is easier to say than to implement. The starting point is a service-level agreement between sales and marketing that defines what marketing will deliver to each tier one account (content, air cover, event coordination, executive engagement) and what sales will deliver in return (account intelligence, named contacts, meeting feedback, CRM hygiene). Without that contract, the program runs on goodwill, and goodwill erodes under commercial pressure.

The broader question of how to build sales and marketing alignment that survives contact with real commercial pressure is covered in depth across the Sales Enablement and Alignment hub, which is worth working through if you are building or rebuilding an ABM program from the ground up.

Technology Stack Considerations for Life Science ABM

The ABM technology market has matured considerably, and the vendor landscape now includes platforms that offer account identification, intent data, personalisation, and reporting in a single environment. The temptation is to buy the platform and build the program around it. That is usually the wrong sequence.

The program design should come first. Which accounts, which personas, which channels, which content, which metrics. The technology should then be selected to support that design, not to define it. I have seen more than one life science company spend six figures on an ABM platform and then spend the next 12 months trying to work out how to use it. The platform is not the strategy.

For most life science vendors at an early stage of ABM maturity, the minimum viable stack is a CRM with good account-level tracking (Salesforce or HubSpot), a LinkedIn Campaign Manager account for paid activation, and a content management system that allows for account-specific landing pages or personalised content experiences. That is enough to run a serious tier one program for 20 to 30 accounts.

Intent data platforms are worth evaluating once the fundamentals are in place, but their value in life science is more limited than vendors suggest. The signal quality for scientific and regulatory roles is weaker than for commercial roles. And intent data tells you what someone is researching, not where they are in a buying cycle. Treat it as one input among several, not as a primary account selection mechanism.

Personalisation technology is worth investing in for tier one accounts once you have the content to personalise. Account-specific landing pages, dynamic email content, and personalised content hubs can meaningfully improve engagement rates. But personalisation technology applied to generic content produces personalised mediocrity. The content brief has to come first.

Common Failure Modes Worth Knowing in Advance

The account list that never gets reviewed. Most ABM programs set an account list at launch and then run it unchanged for 12 months regardless of what changes in the market, in the accounts themselves, or in the company’s own commercial priorities. Quarterly reviews are not a bureaucratic exercise. They are how you keep the program connected to commercial reality.

The content that was built for the buyer and not for the buying committee. A program that produces excellent content for the VP of Clinical Operations but nothing for IT, procurement, or legal will stall at the point where internal consensus is required. Map the committee early and build the content matrix accordingly.

The program that is measured on the wrong things and killed for the wrong reasons. If your CMO is evaluating the ABM program on MQL volume in month four of a 12-month deal cycle, the program will be cancelled before it has had a chance to work. Setting measurement expectations at the outset, with leadership aligned on what ABM is designed to do and on what timeline, is as important as the program design itself.

The sales team that was consulted once and then ignored. Sales buy-in is not a launch activity. It requires ongoing investment. Regular briefings, account-level reviews, feedback loops on what content is landing, and genuine responsiveness when the sales team identifies something that is not working. Without that, the program becomes a marketing activity that sales tolerates rather than a commercial program that sales relies on.

And finally, the program that mistakes sophistication for effectiveness. ABM technology vendors have a commercial interest in selling you complexity. More signals, more personalisation layers, more automation. Some of that is genuinely useful. Some of it is theatre. The question to keep asking is whether each element of the program is influencing a commercial outcome or just making the dashboard look more impressive.

About the Author

Keith Lacy is a marketing strategist and former agency CEO with 20+ years of experience across agency leadership, performance marketing, and commercial strategy. He writes The Marketing Juice to cut through the noise and share what works.

Frequently Asked Questions